Merck gets EMA Committee positive opinion for Pneumococcal 15-valent Conjugate Vaccine in infants, children Ruchika Sharma19 Sep 2022 11:46 AM GMTPneumococcal disease is an infection caused by the bacterium Streptococcus pneumoniae, or pneumococcus.
AstraZeneca Lynparza shows clinically meaningful survival benefit in 1st-line advanced ovarian cancer across two Phase III trials Ruchika Sharma11 Sep 2022 7:45 AM GMTOvarian cancer is one of the most common gynaecologic cancers, with a poor prognosis and a high mortality rate.
Merck Investigational Anticoagulant Therapy MK-2060 gets USFDA fast track designation Ruchika Sharma24 Aug 2022 5:57 AM GMTMK-2060 is a novel inhibitor of Factor XI being investigated for the prevention of thrombosis in patients with end-stage renal disease (ESRD).
USFDA says possible carcinogens found in Merck's Sitagliptin drugs Januvia, Janumet Roshni Dhar13 Aug 2022 12:09 PM GMTThe U.S. Food and Drug Administration said on Tuesday certain samples of sitagliptin, a compound in Merck's diabetes drugs Januvia and Janumet, were...
Health Bulletin 12/August/2022 Roshni Dhar12 Aug 2022 12:03 PM GMTHere are the Top Health stories for the day:Omicron is not mild for the frail, 32 deaths in Delhi in 10 daysThere have been 32 deaths in the past 10...
Merck Specialities ropes in Pratima Reddy as new MD in India Rahul Verma3 Aug 2022 10:18 AM GMTMerck India has recently announced the appointment of Pratima Reddy as the Managing Director for Merck Specialities Pvt. Ltd, the healthcare business...
Merck Healthcare business, BioMed X begin new research project in Oncology Ruchika Sharma2 Aug 2022 12:12 PM GMTGermany: BioMed X, a German independent research institute, has announced the start of its new research project 'Extrachromosomal DNA in Cancer'...
Merck Specialities appoints Pratima Reddy as new MD in India Ruchika Sharma1 Aug 2022 11:58 AM GMTNew Delhi: Merck India has recently announced the appointment of Pratima Reddy as the Managing Director for Merck Specialities Pvt. Ltd, the...
Merck Keytruda fails head and neck cancer trial Rahul Verma21 July 2022 11:30 AM GMTMerck, known as MSD outside the United States and Canada, has announced that the Phase 3 KEYNOTE-412 trial evaluating KEYTRUDA (pembrolizumab),...
Merck Keytruda fails in head and neck cancer trial Ruchika Sharma21 July 2022 9:00 AM GMTKEYTRUDA is an anti-programmed death receptor-1 (PD-1) therapy that works by increasing the ability of the body's immune system to help detect and...
Drugmaker Orion sees inflation hit in H2 after quarterly profit beat Ruchika Sharma17 July 2022 3:30 AM GMTNew Delhi: Finnish drugmaker Orion on Friday reported better-than-expected quarterly earnings helped by strong sales of prostate cancer treatment...
Merck, Orion join hands for Investigational Steroid Synthesis Inhibitor ODM-208 to treat Metastatic Castration-Resistant Prostate Cancer Ruchika Sharma14 July 2022 11:30 AM GMTMerck will make an upfront payment to Orion of USD 290 million, which will be expensed by Merck in the third quarter of 2022 and included in non-GAAP...
